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Daily high-frequency transcranial 
random noise stimulation of 
bilateral temporal cortex in chronic 
tinnitus – a pilot study
peter M. Kreuzer1,3, Timm B. poeppl1,3, Rainer Rupprecht1, Veronika Vielsmeier2,3, 
Astrid Lehner1,3, Berthold Langguth1,3 & Martin Schecklmann1,3
Several studies emphasized the potential of single and multiple transcranial random noise stimulation 
(tRnS) sessions to interfere with auditory cortical activity and to reduce tinnitus loudness. it was 
the objective of the present study to evaluate the use of high-frequency (hf) tRnS in a one-arm pilot 
study in patients with chronic tinnitus. Therefore, 30 patients received 10 sessions of high frequency 
tRNS (100-640 Hz; 2 mA; 20 minutes) over the bilateral temporal cortex. All patients had received 
rTMS treatment for their tinnitus at least 3 months before tRNS. Primary outcome was treatment 
response (tinnitus questionnaire reduction of ≥5 points). The trial was registered at clinicaltrials.gov 
(NCT01965028). Eight patients (27%) responded to tRNS. Exactly the same number of patients had 
responded before to rTMS, but there were only two “double responders” for both treatments. None of 
the secondary outcomes (tinnitus numeric rating scales, depressivity, and quality of life) was significant 
when results were corrected for multiple comparisons. tRnS treatment was accompanied by tolerable 
side effects but resulted in temporal increases in tinnitus loudness in 20% of the cases (2 drop-outs). 
Our trial showed that hf-tRNS is feasible for daily treatment in chronic tinnitus. However, summarizing 
low treatment response, increase of tinnitus loudness in 20% of patients and missing of any significant 
secondary outcome, the use of hf-tRNS as a general treatment for chronic tinnitus cannot be 
recommended at this stage. Differences in treatment responders between tRNS and rTMS highlight the 
need for individualized treatment procedures.
Transcranial random noise stimulation (tRNS) is a non-invasive brain stimulation method using varying alternat-
ing currents to interfere with oscillatory brain activity1. Technically, tRNS represents a special form of transcranial 
alternating current stimulation (tACS) with the current alternating at random normally distributed frequencies. 
tRNS is typically applied as low frequency tRNS (lf-tRNS; frequency range 0,1–100 Hz), high frequency tRNS 
(hf-tRNS; frequency range 101–650 Hz) or as whole frequency tRNS (wf-tRNS; frequency range 0,1–650 Hz). 
tRNS has demonstrated more pronounced effects on motor cortex excitability than other non-invasive brain 
stimulation techniques such as anodal transcranial direct current stimulation (tDCS) or intermittent theta burst 
TMS (transcranial magnetic stimulation) (iTBS)2. Even short-term tRNS of 4 minutes was shown to modulate 
the blood oxygen level dependent (BOLD) signal in the human motor cortex3. Its putative mechanism of action 
is the enhancement of neuronal noise and the decrease of hypersynchronicity4. It was hypothesized that the main 
mechanism of tRNS action was based on repeated subthreshold stimulations, which might prevent homeostasis 
of the system and potentiate task-related neural activity5.
tRNS has been proposed as a treatment option for major depression6, schizophrenia7, neuropathic pain8, and 
fibromyalgia9. It has been shown to modulate pain perception in multiple sclerosis10. hf- tRNS has also been 
found to be able to enhance mathematical ability speed11 and perceptual learning5. In a case report the successful 
treatment of a patient suffering from “Red Ear Syndrome” by high-frequency tRNS was registered12. The “Red Ear 
Syndrome” contains a symptom complex of auricular erythema, attack-like local pain and tinnitus perception13.
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In patients with tinnitus, the effects of single sessions of tDCS, tACS and low-frequency tRNS of the audi-
tory cortex were compared regarding tinnitus loudness and the tinnitus-related distress after stimulation of the 
auditory cortex. A direct comparison of three non-invasive stimulation methods applied to the bilateral auditory 
cortex in 111 tinnitus patients demonstrated that the transient suppressive effect on tinnitus loudness and tinni-
tus related distress was larger after tRNS compared to tDCS and tACS. Both tDCS and tACS induced small and 
non-significant effects on tinnitus perceptions, suggesting lf-tRNS as a superior brain stimulation method for 
tinnitus suppression14.
A recent proof-of-concept study provides evidence on an added value of bilateral temporal lf-tRNS treat-
ment following bifrontal tDCS in 40 patients reporting chronic tinnitus15. The differential effects of high- and 
low-frequency tRNS targeting the auditory cortex were investigated by Joos et al.16 in 154 chronic tinnitus 
patients. A total of 119 patients was treated with lf-tRNS, 19 with hf-tRNS and 16 with wf-tRNS. The effects 
were evaluated applying numeric rating scales for loudness and distress for the states pre- and post-stimulation. 
This study showed a significant reduction in tinnitus loudness for both lf-tRNS and hf-tRNS as well as reduced 
tinnitus-related distress with lf-tRNS. However, hf-tRNS resulted in a more pronounced reduction of loudness 
and distress in pure tone tinnitus than in narrow band noise tinnitus16. This is in line with results derived from 
motor-cortex tRNS applications indicating a higher effectiveness for hf-tRNS1.
Moreover, a sham-controlled trial demonstrated that resting state and steady state activity of the auditory 
cortex were lowered by hf-tRNS in a sample of healthy controls4 indicating that previously described mechanisms 
of actions derived from motor-cortical areas could potentially be transferred to the auditory cortex. Van Doren 
et al. applied EEG measures to examine tRNS induced changes in resting state activity and auditory steady state 
responses (ASSRs). 1000 Hz carrier frequency tones with amplitudes modulated at 20 Hz and 40 Hz applied in 
randomized order were applied as stimuli. Fourteen healthy subjects took part in this placebo-controlled rand-
omized design study; each of the participants received 20 min of tRNS applied over the auditory cortices with 
2 mA. The study resulted in significant increases regarding the ASSR in response to 40 Hz frequency modulated 
tone and non-significant trends towards an increase in mean theta band power and variability of the theta band 
power for the resting state data. Although the authors interpreted their results of tRNS induced increased excita-
bility of the auditory cortex in line with tRNS effects on motor cortex excitability, it should not be concealed that 
stimulation parameters used in this study significantly differ from the “conventional” study protocols targeting 
motor cortical areas with regard to higher stimulation intensities and longer stimulation periods4.
In sum, single studies highlight the capability of different types of tRNS among tES techniques to modulate 
tinnitus loudness and distress effectively. Here we aimed to investigate the effects of multiple sessions of hf-tRNS 
in a one-arm pilot study in patients with chronic tinnitus who had already received repetitive transcranial mag-
netic stimulation.
Methods
We included 30 patients with chronic tinnitus (age: 49.2 ± 10.9 years; sex: 4 females; mean hearing loss averaged 
over both sides and the range of the standard audiogram (250 Hz–8 kHz): 20.1 ± 12.5 dB HL; tinnitus distress: 
45.8 ± 19.3 [range: 9–80] tinnitus questionnaire (TQ17; total score); tinnitus laterality: one purely right-sided, 
seven purely left-sided, 22 with tinnitus in both ears or within head; tinnitus duration: 96.0 ± 73.7 months).
Patients were stimulated with 2 mA (0 off-set) over the bilateral temporal cortex for 20 minutes (ramp times: 
10 s; 5 cm × 7 cm electrodes). The cathode was always applied to the left hemisphere and the anode to the right 
hemisphere with the inferior center of the electrode over the EEG position T7/T8. The long side of the electrodes 
was oriented in anterior-posterior direction. We used hf-tRNS (100–640 Hz) applied by a NeuroConn (Ilmenau, 
Germany) DC-Stimulator Plus device for ten days. Stimulation procedures were similar to earlier published data 
in healthy controls4. Patients were treated for 10 consecutive working days beginning with Monday and pausing 
at weekend.
Study visits were done in the hospital, included measurement of tinnitus characteristics and questionnaires, 
and took place at baseline (treatment day 1), week2 (treatment day 10/end of treatment), follow-up visits were 
conducted in week4 and 12 (two and ten weeks after treatment, respectively).
All patients had previously received a rTMS treatment series 22.6 ± 27.1 months (range 3–108 months) before 
enrolment in the tRNS study. However, the main focus of the study was the investigation of tRNS in tinnitus in 
a sample of patients pre-treated with rTMS. However, it was not pre-specified that rTMS has to be standardized 
with respect to the rTMS protocol and the time difference between both treatments. The rationale was to be 
able to estimate differences in the efficacy of both treatments. Tinnitus distress for the patients was comparable 
between the baseline visit of the rTMS and the tRNS treatment (rTMS: 44.8 ± 17.6; tRNS: 46.6 ± 18.9; T = 1.073; 
df = 25; p = 0.293). Detailed rTMS treatment parameters differed between patients due to the participation in 
different rTMS studies in our center. We contrasted both types of treatment (tRNS vs. rTMS). For an overview of 
demographics and rTMS study parameters see supplementary information.
Treatment response (primary outcome) was defined as reduction in the tinnitus questionnaire (TQ; range 
0–84)17 of five points or more according to Adamchic et al.18 from baseline to week 12. The Tinnitus Questionnaire 
(TQ) was initially developed by Hallam et al.19 and has been translated and adapted by Goebel and Hiller in 
199417. This instrument differentiates between emotional and cognitive distress, auditory perceptual difficulties 
and self-experienced intrusiveness produced by the tinnitus. Broadly accepted as an outcome measure in clinical 
studies on chronic tinnitus, the TQ can be employed both for comparative studies in different tinnitus-related 
institutions and for the evaluation of the relative effects of different treatment approaches.17
To investigate possible association of treatment response between tRNS and rTMS we calculated a 
Chi-Square-test. Secondary outcomes were changes in TQ, Major Depression Inventory (MDI) by Bech et al.20, 
numeric rating scales for tinnitus loudness, discomfort, annoyance, ignorability and unpleasantness (range 0–10 
numeric analog scale), and WHO Quality of Life questionnaire (WHOQOL-BREF)21 over the course of the 
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trial. Data were assessed according to international standards22,23 and registered in a tinnitus database following 
ICH-GCP-regulations24. Secondary outcome variables were used for direct contrast between baseline and final to 
see if tRNS has treatment effects. Analyses of variance with the dependent variables TQ, MDI, numeric ratings, 
and quality of life and with the independent factors time (visits) and treatment (tRNS, rTMS) were used to see if 
there is a difference of tRNS with respect to pre-treatment with rTMS. All results from statistical analyses of sec-
ondary outcomes were also calculated with corrections for multiple comparisons by using Bonferroni corrections. 
All data are displayed as mean ± standard deviation if not otherwise labelled. Significance threshold was set to 5%. 
We conducted a per-protocol analysis (n = 26). Missing data were replaced with last-observation-carried-forward 
method.
hf-tRNS is a relatively new type of brain stimulation in daily treatment. Therefore, further objectives were 
the assessment of adverse events and safety information by the application of standardized questionnaires at all 
visits. Data were available for 18 patients who answered on a 10-point numeric scale (1 (not) to 10 (extreme)) 
the occurrence of side effects. Cognitive effects were tested with measures of tonic and phasic alertness, working 
memory and divided attention as elicited by the Test of Attentional Performance (Psytest, Germany). Cognitive 
data were available for 23 patients.
Data were assessed according to international standards25 and registered in an established tinnitus data-
base following ICH-GCP-regulations22,23. The trial was registered on clinicaltrials.gov (NCT01965028; date: 
14/10/2013) and approved by the local ethics committee of the University Hospital Regensburg (13-101-0143). 
All participants gave written informed consent after a comprehensive explanation of the study procedures. All 
methods were performed in accordance with the relevant guidelines and regulations.
Results
Adverse events. Six patients perceived temporal increases in tinnitus loudness (for two of them it was 
unbearable and they dropped out at treatment day 6 and 8; transient increases can occur during treatment thus 
the other patients did not quit) and two patients reported headaches (one drop-out). One patient did not finish 
the treatment due to personal reasons (overall four drop-outs). Reported adverse effects were the perception 
of mild to extreme pain (17% out of 18 patients), tingling (72%), burning (28%), tiredness (56%), nervousness 
(22%), concentration problems (39%), visual problems (11%), headaches (39%), itching (39%), dizziness (11%), 
lightnings (6%) and sounds (28%) during or after the stimulation. 44% reported sleeping problems. In general 
17% rated the stimulation as unpleasant. One patient presented high ratings of all side effects. With respect to 
cognitive effects of the stimulation, quantitative analyses of norm T scores showed mean numeric increases over 
the course of the trial (Fig. 1). A detailed view on the single values indicates increases in performance of the 
majority of the patients, but also decreases in single parameters up to 7 out of 23 patients. Critical values are 
data below a T score of 30 which indicate norm-deviant values. Only 3 patients showed deviant values for single 
parameters after the stimulation. Most of them were already deviant or at borderline level at the beginning of the 
treatment. Another critical parameter would be decrease in performance by one standard deviation which was 
the case for 15 single values (out of 158). Compared with this 22 single values increased by at least one standard 
deviation.
primary outcome. Eight patients fulfilled the response criterion after tRNS treatment. There was a descrip-
tive decrease in TQ from baseline to final visit for tRNS. In comparison, 8 patients had shown a response to 
previous rTMS treatment. But only two of them responded to both rTMS and tRNS. Chi-Square-test indicate no 
significant association (χ² = 0181; df = 1; p = 0.671). For detailed information with respect to kind of rTMS treat-
ment and response to rTMS and tRNS see supplementary information. Most of the rTMS treatments included 
prefrontal and temporal/temporoparietal stimulation and indicated no specific association of treatment response 
and kind of treatment. This study was not designed as study to investigate the additive effects of rTMS treat-
ment and tRNS treatment. rTMS treatment serves as control condition for statistical reasons but was not a priori 
planned as controlled study.
Secondary outcomes. Contrasts from baseline to final visit for tRNS treatment resulted in significant 
decreases for tinnitus annoyance, unpleasantness and depressivity (Table 1). Analyses of variance with the 
dependent variables TQ, MDI, numeric ratings, and quality of life and with the independent factors time and 
Figure 1. Tinnitus Questionnaire (TQ) total score over the course of the trial.
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treatment showed no significant effects of time (all F-values < 2.701; df = 3,75; all p-values > 0.052) or time by 
treatment (all F-values < 2.627; df = 3,75; all p-values > 0.056) except for the numeric rating “unpleasantness of 
tinnitus” (time by treatment: F = 4.294; df = 3,75; p = 0.008) and the quality of life domain “physical well-being” 
(time by treatment: F = 2.767; df = 3,69; p = 0.048). “Unpleasantness of tinnitus” decreased from baseline to week 
2 (baseline vs. week 2 for tRNS: p = 0.002), but was also higher at baseline of the tRNS trial as compared to the 
rTMS treatment (tRNS vs. rTMS for baseline: p = 0.004;). Physical well-being decreased from week 2 to week 4 
during the rTMS treatment (week 2 vs. week 4 for rTMS: p = 0.010). All observations for secondary outcome 
measures did not survive correction for multiple comparisons.
Discussion
Treatment of chronic tinnitus with hf-tRNS is easily applicable, showed tolerable side effects, but resulted in 
temporal increases in tinnitus loudness in 20% of the cases leading to two drop-outs. One advantage over rTMS 
is that tRNS is not associated with pulsed local aversive sensations inherent to TMS stimulation. During tRNS 
patients report either constant slight tingling or no local sensations at all. As tRNS provides a balanced current 
stimulation it is considered even safer than tDCS, which induces a polarizing stimulation possibly leading to skin 
lesions under certain conditions1. Accordingly, no erythema or burning skin lesion were observed in our study. 
In our clinical cohort no significant effects on cognitive functioning were detected assuming tRNS of the bilateral 
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tRNS 44.8 ± 17.6 45.6 ± 17.3 47.4 ± 18.3 45.7 ± 19.7 T = −0.952
p = 0.350
d = 0.187
time: F = 0.638; df = 3,75; p = 0.593
treatment: F = 0.106; df = 1,25; p = 0.747
time × treatment: F = 1.298; df = 3,75; 
p = 0.281
rTMS 46.6 ± 18.9 47.2 ± 20.1 46.1 ± 19.9 45.1 ± 18.2
tinnitus loudness 
rating (0–10)
tRNS 7.4 ± 1.6 6.9 ± 1.6 6.9 ± 1.8 7.0 ± 1.8 T = −1.122
p = 0.273
d = 0.220
time: F = 0.850; df = 3,75; p = 0.471
treatment: F = 0.118; df = 1,25; p = 0.734
time × treatment: F = 1.343; df = 3,75; 
p = 0.267




tRNS 7.8 ± 1.5 7.0 ± 1.9 7.2 ± 1.7 7.3 ± 1.7 T = −1.759
p = 0.091
d = 0.345
time: F = 2.701; df = 3,75; p = 0.052
treatment: F = 0.045; df = 1,25; p = 0.833
time × treatment: F = 1.243; df = 3,75; 
p = 0.300




tRNS 7.6 ± 1.6 6.9 ± 1.8 6.9 ± 2.0 6.9 ± 1.9 T = −2.095
p = 0.047
d = 0.411
time: F = 0.855; df = 3,75; p = 0.468
treatment: F = 0.607; df = 1,25; p = 0.443
time × treatment: F = 2.627; df = 3,75; 
p = 0.056




tRNS 7.6 ± 1.9 7.0 ± 2.2 7.0 ± 2.3 7.0 ± 2.5 T = −1.213
p = 0.237
d = 0.243
time: F = 1.010; df = 3,72; p = 0.393
treatment: F = 0.416; df = 1,24; p = 0.525
time × treatment: F = 0.370; df = 3,72; 
p = 0.775




tRNS 7.7 ± 1.6 6.7 ± 1.8 6.9 ± 1.8 7.0 ± 1.8 T = −2.360
p = 0.026
d = 0.463
time: F = 1.728; df = 3,75; p = 0.168
treatment: F = 0.260; df = 1,25; p = 0.615
time × treatment: F = 4.294; df = 3,75; 
p = 0.008
rTMS 6.9 ± 2.1 6.9 ± 1.9 7.1 ± 2.2 7.1 ± 2.4
quality of life 
physical health 
(4–20*)
tRNS 13.5 ± 3.3 13.7 ± 2.9 13.5 ± 3.1 14.1 ± 2.8 T = 1.748
p = 0.093
d = 0.343
time: F = 1.120; df = 3,69; p = 0.347
treatment: F = 0.004; df = 1,23; p = 0.949
time × treatment: F = 2.767; df = 3,69; 
p = 0.048
rTMS 138 ± 3.1 14.0 ± 2.6 13.4 ± 2.3 13.5 ± 2.7




tRNS 13.3 ± 3.3 13.6 ± 2.9 13.8 ± 2.8 13.5 ± 2.8 T = 0.669
p = 0.509
d = 0.131
time: F = 0.373; df = 3,69; p = 0.772
treatment: F = 0.066; df = 1,23; p = 0.800
time × treatment: F = 1.651; df = 3,69; 
p = 0.186





tRNS 15.9 ± 2.5 15.6 ± 2.9 15.6 ± 2.7 15.5 ± 2.9 T = −0.781
p = 0.442
d = 0.153
time: F = 0.219; df = 3,69; p = 0.883
treatment: F = 3.483; df = 1,23; p = 0.075
time × treatment: F = 0.900; df = 3,69; 
p = 0.446
rTMS 14.9 ± 3.1 15.2 ± 2.9 14.8 ± 3.0 15.0 ± 2.5
quality of life 
environment 
(4–20*)
tRNS 16.0 ± 1.6 16.1 ± 1.7 16.3 ± 1.7 16.1 ± 1.8 T = 0.368
p = 0.716
d = 0.072
time: F = 0.007; df = 3,69; p = 0.999
treatment: F = 0.127; df = 1,23; p = 0.725
time × treatment: F = 1.072; df = 3,69; 
p = 0.367
rTMS 16.2 ± 1.6 16.1 ± 1.7 15.9 ± 1.7 16.1 ± 1.7
depressivity 
(0–50)
tRNS 9.1 ± 6.2 8.5 ± 5.4 8.7 ± 5.8 7.9 ± 5.8 T = −2.238
p = 0.034
d = 0.439
time: F = 0.670; df = 3,57; p = 0.574
treatment: F = 0.790; df = 1,19; p = 0.385
time × treatment: F = 0.683; df = 3,57; 
p = 0.566
rTMS 7.6 ± 5.2 7.8 ± 4.7 8.4 ± 5.1 8.1 ± 5.1
change in clinical 
global impression 
(1–7*)
tRNS — 3.8 ± 0.7 4.0 ± 0.6 3.7 ± 0.7
n.a.
time: F = 1.627; df = 2,50; p = 0.207
treatment: F = 5.430; df = 1,25; p = 0.028
time × treatment: F = 0.473; df = 2,50; 
p = 0.648
rTMS — 4.1 ± 0.8 4.3 ± 0.9 4.2 ± 0.9
Table 1. Descriptive statistics of the dependent variables over the course of the trials. *High values indicate 
high quality of life.
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by one standard deviation in single cases did not exceed the number of increases of performance by one standard 
deviation. Nonetheless, single cases with amelioration TAP-scores suggest that hf-tRNS may have potential to 
improve cognitive functioning under certain conditions. Even if we have no systematic or obvious deterioration 
in cognitive functions, further detailed investigations seem to be required.
tRNS treatment was detected to be effective in 31% of the patients who completed the treatment indicated by 
clinical response defined by an at least 5 point reduction in the TQ (the response rate in the intention-to-treat 
population was 27%). This response rate was comparable to rTMS efficacy in earlier trials of our center26.
A potential objection of the present study might be the missing measurement of individual hearing loss, as this 
is well known and broadly accepted as a central risk factor for the development of chronic tinnitus27. However, 
in predictor analyses concerning brain stimulation methods in chronic tinnitus, no impact of hearing level on 
clinical outcome could be detected so far28.
Notably, treatment response to rTMS in our study sample did not predict treatment response to tRNS. Please 
note, that it was not the intention of the present study to investigate the additive effects of rTMS treatment and 
tRNS treatment (e.g. there was no “tRNS only” control condition, and the rTMS protocols vary significantly 
between the participants). In addition to these arguments related to study design, potential carry-over effects 
cannot reliably and totally be ruled out although the authors consider them as unlikely in the view of the long 
(minimum 3 months) wash-out periods between the two courses of brain stimulation techniques. The exact time 
spans are proved in detail for each participant in a table in supplementary information. The authors suggest not to 
over-interpret the comparing analyses between rTMS and tRNS treatment. However, they feel that it may indeed 
serve as a helpful tool to estimate the potential of hf-tRNS treatment in a naturalistic setting of a variety of differ-
ential brain stimulation techniques targeting chronic tinnitus perceptions.
Only two “double responders” according to the criterion mentioned above were detected in our study cohort. 
This observation might favor an individualized treatment approach. For brain stimulation techniques, such an 
approach could be realized by utilizing single test sessions as predictors for daily treatment. Such attempts have 
already been suggested in rTMS applications for different stimulation targets and parameters providing inno-
vative treatment strategies in chronic tinnitus29. However, it has to be stated that in the presented study we did 
not evaluate possible immediate effects of single-sessions of tRNS in our patients. These issues will have to be 
addressed in upcoming studies.
Specific changes in tinnitus unpleasantness after tRNS in contrast to rTMS might be explained by the stim-
ulation of more medial temporal areas such as posterior insula or hippocampus as a summation effect of elec-
tric currents in border regions linking different types of tissues4. However, we would strongly suggest not to 
over-interpret this result as it might be purely attributable to multiple testing. In line with this argumentation we 
abstain from over-interpretation of the physical quality of life findings. No other secondary outcome over the 
course of the treatment was significant. In sum, for the whole group we could not demonstrate efficacy of hf-tRNS 
for treatment of chronic tinnitus.
A factor of uncertainty is the use of hf-tRNS (100–640 Hz) as there is evidence for efficacy of lf-tRNS in 
chronic tinnitus14–16. In sum, most tRNS studies in tinnitus used lf-tRNS and showed efficacy. One direct compar-
ison of hf- and lf-rRNS turned out that lf-tRNS might be superior to hf-tRNS with respect to tinnitus distress16. 
Both interventions were similar effective with respect to tinnitus loudness. Hf-tRNS turned out to be more effec-
tive for pure-tone in contrast to noise-like tinnitus. Although there is evidence from steady state EEG data and 
auditory evoked potentials that tRNS effect to the auditory might parallel the effects in motor-cortical areas4, the 
optimal frequency spectrum for stimulation of the auditory cortex in tinnitus patients remains a matter of debate.
Another limitation of our study is the fact, that all patients had already absolved one rTMS treatment series 
introducing a possible selection bias. However, the fact that positive response to rTMS treatment did not predict 
response in the present tRNS-based study suggests different underlying mechanisms of both stimulation tech-
niques. The authors are well aware of the fact that unspecific effects cannot be reliably ruled out. Nevertheless, the 
fact that all patients already participated in a neurostimulation treatment study before, makes it rather improbable 
that the observed effects are purely unspecific effects, as unspecific effects of rTMS and tRNS should resemble 
each other. In addition, an optimal design would have included a placebo group/condition. For ethical reasons, 
we decided to use a real-life application using a within-subjects design with the factor of different conditions.
Taken together, our pilot study provides evidence for the feasibility of high-frequency tRNS in the treatment 
of chronic tinnitus and demonstrated an identical low response rate compared to transcranial magnetic stimula-
tion in a study cohort which was treated almost two years after the first neurostimulation treatment attempt with 
rTMS. In sum, the trial was negative as no secondary outcome measure was significant including TQ (the basis for 
the definition of treatment response). As the subgroup of patients who responded to hf-tRNS differed from rTMS 
responders, the results advocate to further focus on individualized treatment approaches.
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